Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have been assigned a consensus recommendation of “Moderate Buy” from the thirteen research firms that are currently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation, ten have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $365.40.

KRYS has been the subject of several research analyst reports. Wall Street Zen lowered Krystal Biotech from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Evercore reiterated an “outperform” rating and issued a $300.00 price objective on shares of Krystal Biotech in a report on Tuesday, May 5th. Chardan Capital raised Krystal Biotech to a “strong-buy” rating in a research note on Monday, August 3rd. Citigroup raised their target price on Krystal Biotech from $378.00 to $386.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Finally, Weiss Ratings downgraded Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research report on Tuesday, August 18th.

Krystal Biotech Stock Performance

Shares of KRYS stock opened at $346.58 on Monday. The firm’s 50 day moving average price is $347.03 and its 200-day moving average price is $301.54. Krystal Biotech has a one year low of $136.73 and a one year high of $382.54. The firm has a market cap of $10.26 billion, a P/E ratio of 43.43 and a beta of 0.53.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, August 3rd. The company reported $1.79 earnings per share for the quarter, topping analysts’ consensus estimates of $1.70 by $0.09. The firm had revenue of $119.22 million during the quarter, compared to analysts’ expectations of $120.93 million. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. As a group, research analysts predict that Krystal Biotech will post 7.68 EPS for the current fiscal year.

Insider Activity

In related news, Director Dino A. Rossi sold 25,000 shares of the company’s stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the sale, the director directly owned 50,000 shares of the company’s stock, valued at $16,456,000. This represents a 33.33% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP John Charles Thomas sold 1,000 shares of the stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $347.27, for a total transaction of $347,270.00. Following the sale, the executive vice president owned 1,000 shares in the company, valued at approximately $347,270. This trade represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 51,642 shares of company stock valued at $16,471,923. 13.10% of the stock is currently owned by company insiders.

Institutional Trading of Krystal Biotech

Large investors have recently modified their holdings of the stock. Royal Bank of Canada boosted its holdings in Krystal Biotech by 145.2% in the first quarter. Royal Bank of Canada now owns 1,628 shares of the company’s stock valued at $294,000 after purchasing an additional 964 shares during the period. AQR Capital Management LLC increased its holdings in Krystal Biotech by 29.9% during the 1st quarter. AQR Capital Management LLC now owns 12,131 shares of the company’s stock worth $2,187,000 after purchasing an additional 2,792 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Krystal Biotech by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company’s stock worth $2,870,000 after purchasing an additional 688 shares during the period. Empowered Funds LLC acquired a new stake in Krystal Biotech in the 1st quarter valued at about $218,000. Finally, Cetera Investment Advisers raised its position in Krystal Biotech by 107.9% in the 2nd quarter. Cetera Investment Advisers now owns 4,344 shares of the company’s stock valued at $597,000 after purchasing an additional 2,255 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.